If you've been a broker for a couple of decades, manipulation must indeed be so taken for granted that it becomes meaningless issue and just background noise.
Attempt to seize the discussion and direct it towards absolute certainties...that's the way.
But, naturally, this all precludes any other capital that might be incoming, for example partnership deals, milestone payments or product royalties and/or revenues. All of which are somewhat indeterminate, both in timing and quantity, as we have seen.
No uncertainties will be tolerated and certainly not any balance in investor's minds to future revenue and deals in a risk v reward equation. No these must be either dead certainties. or discarded. We aren't allowed to do what other biotech investors do and actually balance our uncertainties with decent guesses taking into account all relevant information. If it's not income and costs on a spread sheet it doesn't exist.
Plus, because we must accept the market is not manipulated, we must accept the SP reflects fair value...there is a kind of circular genius in there worthy of a Macbank report.
Wait! what about other analysts reports? Oh they don't matter ? and there are more to come from the US but let's not go there...let's focus on the negatives shall we?
You may not to take anything that the CEO says at face value and each and every comment must be nailed down with exactitude. Forget what he said about the reason for the Celgene extension being so they can negotiate on a wider range of applications. Clearly bunk, even though it was stated at the AGM. The fact that we are in Stage 3 clinical trials and efficacy has been proven in Stage 2 would not have concentrated any potential partner's negotiating minds. Not at all! No progress has been made. Forget it.
Same with the CEO's statement that the market has underestimated the revenue from Japan. He must be dreaming! Even though that kind of information is not yet in the public domain and would be confidential. Demand that he release it pronto. That's realistic, isn't it?
If anyone gets in your way, hammer away with irrelevancies and make it your full time job to ignore their points and pretend they are making different ones. Goad everyone into what they should be talking about and give them a barrage of detail about absolutes to do it. Even though this about risk v reward, always act as if it's about risk only. Do not give any oxygen to any discussion about positives, it's too woolly to be allowed.
Are we are supposed to accept this prolonged 'analysis' which disregards any positive outcomes are unquantifiable and therefore irrelevant, even though the exact nature and extent of market manipulation is unquantifable it must also be irrelevant! There is a circular genius to this thinking that should be admired.
NO. NO. and NO. Thanks all the same.
PS why not buy the minimum allocation of $500 of shares so you can actually become a shareholder and direct these pressing questions to MSB management yourself? Indeed many of your questions can indeed be answered but it would take someone a lot of time to do it, and that's what you're banking on...that nobody will be able to keep up with your barrage of questions and juxtapositions. Just look at that effort.
Sadly you claim to not be a shorter either. But there is no rational reason for your fixation on MSB...surely there are other worthy biotechs of your persistent charm and attentions. Over 14 posts in one day the other day and back again. But we are supposed to accept that it's a genuine lament for existing shareholders? It's nothing if not audacious.
MSB Price at posting:
$1.95 Sentiment: Buy Disclosure: Held
(20min delay)